Endocrinology Archives - Page 4 of 8 - Corcept Therapeutics

Prevalence of hypercortisolism in patients with difficult-to-control type 2 diabetes and high blood pressure: Results from CATALYST

December 12, 2024

Handelsman et al. • 2024 • WCIRDC

Open-label Extension Study Evaluating the Safety and Efficacy of Long-term Use of Relacorilant in Patients With Endogenous Hypercortisolism (Cushing Syndrome): Results from the First Interim Analysis

November 25, 2024

Badiu et al. • 2024 • AACE MENA 2024 Congress

Relacorilant Maintained Hypertension Improvement in Long-term Follow-up of Patients With Endogenous Hypercortisolism (Cushing Syndrome)

November 25, 2024

Gilis-Januszewska et al. • 2024 • AACE MENA 2024 Congress

Hypercortisolism Impact on Hypertension and Hyperglycemia and Beyond

June 7, 2024

Ralph A. DeFronzo • 2024 • Heart in Diabetes 2024
Posted with permission of the presenter.

Medical Treatment of Hypercortisolism with Relacorilant: Final Results of the Phase 3 GRACE Study

June 7, 2024

2024 • Heart in Diabetes 2024

Results From Grace, a Phase 3 Double-blind, Randomized-withdrawal Study of the Selective Glucocorticoid Receptor Modulator Relacorilant for the Treatment of Endogenous Hypercortisolism (Cushing Syndrome)

June 3, 2024

2024 • ENDO 2024

Rapid Clinical Improvements in a Patient with Difficult-to-Control Type 2 Diabetes by Addressing Underlying Hypercortisolism with Mifepristone

May 14, 2024

2024 • AACE 2024

Difficult-to-Control Diabetes: Is Cortisol at Play?

January 8, 2024

• 2023 • Roundtable Discussion

Impact of Surgery or Medical Treatment With the Selective Glucocorticoid Receptor Modulator Relacorilant on Hypercoagulopathy in Patients With Cushing Syndrome

July 6, 2023

Simeoli et al. • 2023 • Italian Society of Endocrinology National Congress 2023

Impact of Surgery or Medical Treatment With the Selective Glucocorticoid Receptor Modulator Relacorilant on Hypercoagulopathy in Patients With Cushing Syndrome

June 20, 2023

Simeoli et al. • 2023 • ENDO 2023